These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 25609246)

  • 1. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
    Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
    Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
    Kindler HL; Richards DA; Garbo LE; Garon EB; Stephenson JJ; Rocha-Lima CM; Safran H; Chan D; Kocs DM; Galimi F; McGreivy J; Bray SL; Hei Y; Feigal EG; Loh E; Fuchs CS
    Ann Oncol; 2012 Nov; 23(11):2834-2842. PubMed ID: 22700995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
    Okusaka T; Ikeda M; Fukutomi A; Kobayashi Y; Shibayama K; Takubo T; Gansert J
    Jpn J Clin Oncol; 2014 May; 44(5):442-7. PubMed ID: 24782485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
    McCaffery I; Tudor Y; Deng H; Tang R; Suzuki S; Badola S; Kindler HL; Fuchs CS; Loh E; Patterson SD; Chen L; Gansert JL
    Clin Cancer Res; 2013 Aug; 19(15):4282-9. PubMed ID: 23741071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
    Cohn AL; Tabernero J; Maurel J; Nowara E; Sastre J; Chuah BYS; Kopp MV; Sakaeva DD; Mitchell EP; Dubey S; Suzuki S; Hei YJ; Galimi F; McCaffery I; Pan Y; Loberg R; Cottrell S; Choo SP
    Ann Oncol; 2013 Jul; 24(7):1777-1785. PubMed ID: 23510984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
    Philip PA; Goldman B; Ramanathan RK; Lenz HJ; Lowy AM; Whitehead RP; Wakatsuki T; Iqbal S; Gaur R; Benedetti JK; Blanke CD
    Cancer; 2014 Oct; 120(19):2980-5. PubMed ID: 25041791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
    Infante JR; Somer BG; Park JO; Li CP; Scheulen ME; Kasubhai SM; Oh DY; Liu Y; Redhu S; Steplewski K; Le N
    Eur J Cancer; 2014 Aug; 50(12):2072-81. PubMed ID: 24915778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
    Wolpin BM; O'Reilly EM; Ko YJ; Blaszkowsky LS; Rarick M; Rocha-Lima CM; Ritch P; Chan E; Spratlin J; Macarulla T; McWhirter E; Pezet D; Lichinitser M; Roman L; Hartford A; Morrison K; Jackson L; Vincent M; Reyno L; Hidalgo M
    Ann Oncol; 2013 Jul; 24(7):1792-1801. PubMed ID: 23448807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
    Deplanque G; Demarchi M; Hebbar M; Flynn P; Melichar B; Atkins J; Nowara E; Moyé L; Piquemal D; Ritter D; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Hammel P
    Ann Oncol; 2015 Jun; 26(6):1194-1200. PubMed ID: 25858497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
    Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma.
    Benson AB; Wainberg ZA; Hecht JR; Vyushkov D; Dong H; Bendell J; Kudrik F
    Oncologist; 2017 Mar; 22(3):241-e15. PubMed ID: 28246206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
    Van Cutsem E; Vervenne WL; Bennouna J; Humblet Y; Gill S; Van Laethem JL; Verslype C; Scheithauer W; Shang A; Cosaert J; Moore MJ
    J Clin Oncol; 2009 May; 27(13):2231-7. PubMed ID: 19307500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
    Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
    J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
    Hu ZI; Bendell JC; Bullock A; LoConte NK; Hatoum H; Ritch P; Hool H; Leach JW; Sanchez J; Sohal DPS; Strickler J; Patel R; Wang-Gillam A; Firdaus I; Yu KH; Kapoun AM; Holmgren E; Zhou L; Dupont J; Picozzi V; Sahai V; O'Reilly EM
    Cancer Med; 2019 Sep; 8(11):5148-5157. PubMed ID: 31347292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
    Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M
    Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
    Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
    J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.
    Evans TRJ; Van Cutsem E; Moore MJ; Bazin IS; Rosemurgy A; Bodoky G; Deplanque G; Harrison M; Melichar B; Pezet D; Elekes A; Rock E; Lin C; Strauss L; O'Dwyer PJ
    Ann Oncol; 2017 Feb; 28(2):354-361. PubMed ID: 27998964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
    Picozzi VJ; Ramanathan RK; Lowery MA; Ocean AJ; Mitchel EP; O'Neil BH; Guarino MJ; Conkling PR; Cohen SJ; Bahary N; Frank RC; Dragovich T; Bridges BB; Braiteh FS; Starodub AN; Lee FC; Gribbin TE; Richards DA; Lee M; Korn RL; Pandit-Taskar N; Goldsmith SJ; Intenzo CM; Sheikh A; Manzone TC; Horne H; Sharkey RM; Wegener WA; O'Reilly EM; Goldenberg DM; Von Hoff DD
    Eur J Cancer; 2015 Sep; 51(14):1857-64. PubMed ID: 26187510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
    Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
    Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
    Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.